M.D. Anderson Cancer Center: Mycosis Fungoides trials

The registry lists 10 Mycosis Fungoides studies with M.D. Anderson Cancer Center as lead sponsor. 2 are open to participants now and 3 have results posted.

Phase 1 3Phase 2 7Phase 4 1No phase 1(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Long-term Outcomes Associated With Juvenile-onset Mycosis Fungoides and Lymphomatoid PapulosisRecruitingNCT06207812
• Effectiveness of Concurrent Ultra-Low-Dose Total-Skin Electron Beam Therapy and Brentuximab Vedotin Given Quarterly Over 12 Months for Patients With Mycosis FungoidesRecruitingNCT05357794Phase 2
• Modified Immune Cells (AFM13-NK) and A Monoclonal Antibody (AFM13) in Treating Patients With Recurrent or Refractory CD30 Positive Hodgkin or Non-Hodgkin LymphomasCompletedNCT04074746Phase 1/2Results posted
• Study of Pembrolizumab (MK-3475) in Combination With RomidepsinActive, not recruitingNCT03278782Phase 1/2Results posted
• Study of Total Skin Electron Beam Therapy (TSEBT) in Stage IB-IIIA Mycosis FungoidesCompletedNCT01073267Phase 2Results posted
• Ultra Low Dose Radiation Therapy in Treating Patients With Mycosis FungoidesActive, not recruitingNCT03398161Phase 2
• Romidepsin, Ifosfamide, Carboplatin, and Etoposide in Treating Participants With Relapsed or Refractory Peripheral T-Cell LymphomaCompletedNCT01590732Phase 1
• SGN-35 in CD30-positive Lymphoproliferative Disorders (ALCL), Mycosis Fungoides (MF), and Extensive Lymphomatoid Papulosis (LyP)Active, not recruitingNCT01352520Phase 2
• Photopheresis as an Interventional Therapy for the Treatment of CTCL (Cutaneous T-Cell Lymphoma, Mycosis Fungoides) Stage 1A, 1B, 2ACompletedNCT00221039Phase 4
• Phase II Study Of Roferon and Accutane For Patients With T-Cell MalignanciesCompletedNCT00038376Phase 2